Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 29, 2007

MGI Obtains Rights to Thrombocytopenia Treatment for $45M

  • MGI Pharma obtained the rights to develop AkaRx’ antithrombotic agent as well as the option to acquire the company for $45 million.

    MGI may acquire all of AkaRx’s capital stock any time prior to January 8, 2010. If the company does exercise its option, MGI will make additional payments of approximately $255 million at that time.

    The development and license agreement is related to AKR-501, and no additional milestone or royalty fees are associated with the transaction. MGI will assume responsibility for certain development activities during the option period.
    AKR-501 is an orally available small molecule thrombopoietin mimetic being developed for the treatment of thrombocytopenia. It is a full agonist that targets the c-Mpl receptor on platelet-producing cells to stimulate platelet production.

    MGI also obtained rights to AKR-201, a metabolite of thyroid hormone targeting thyroid cancer. The compound is in preclinical development and has received an orphan drug designation.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »